IDEXX Laboratories, Inc. $IDXX Shares Sold by The Manufacturers Life Insurance Company

Posted by Brenda Bartman on Aug 2nd, 2026

The Manufacturers Life Insurance Company decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 25.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 42,655 shares of the company’s stock after selling 14,464 shares during the period. The Manufacturers Life Insurance Company’s holdings in IDEXX Laboratories were worth $23,967,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. KBC Group NV increased its stake in shares of IDEXX Laboratories by 76.9% during the 4th quarter. KBC Group NV now owns 309,380 shares of the company’s stock worth $209,305,000 after purchasing an additional 134,493 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $3,666,459,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in IDEXX Laboratories by 4.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 209,106 shares of the company’s stock valued at $141,466,000 after buying an additional 8,626 shares in the last quarter. NewEdge Wealth LLC grew its holdings in IDEXX Laboratories by 122.3% during the 4th quarter. NewEdge Wealth LLC now owns 6,597 shares of the company’s stock valued at $4,463,000 after buying an additional 3,629 shares during the last quarter. Finally, Prospera Financial Services Inc acquired a new stake in IDEXX Laboratories during the 4th quarter valued at $4,188,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.0%

Shares of IDEXX Laboratories stock opened at $559.07 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The firm has a market cap of $44.10 billion, a PE ratio of 41.17, a P/E/G ratio of 3.06 and a beta of 1.55. The business’s fifty day moving average is $557.36 and its two-hundred day moving average is $590.40. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of analyst reports. UBS Group cut their price target on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a report on Monday, July 27th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Finally, Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $749.00.

Get Our Latest Analysis on IDXX

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.